DEA tells Congress it's considering easing marijuana restrictions

The Drug Enforcement Administration told lawmakers it is "now conducting its review" of whether to soften federal regulation of marijuana under the Controlled Substances Act.

Why it matters: Moving marijuana off the list of Schedule I drugs would mark a significant shift away from federal enforcement of a drug that dozens of states have legalized or decriminalized in recent years.

It would also clear obstacles for the growing cannabis industry, which has struggled to access banking services due to continued federal restrictions.
Driving the news: In a letter to Rep. Earl Blumenauer (D-Ore.) last month, first reported by Punchbowl News on Wednesday, DEA official Michael Miller wrote that the agency has "the final authority to schedule, reschedule or deschedule" drugs under the Controlled Substances Act.

Marijuana is currently a Schedule I substance — which are considered to have the highest potential for abuse and safety risk with no currently accepted medical use — along with drugs such as heroin and LSD.
Blumenauer and dozens of other lawmakers in both parties sent DEA Administrator Anne Milgram a letter in October calling to "end the harmful federal marijuana prohibition and help our law enforcement officers appropriately prioritize public safety."

The backdrop: President Biden in 2022 issued a directive pardoning all prior federal marijuana possession offenses and ordering the Department of Health and Human Services to "review expeditiously how marijuana is scheduled under federal law."
more
https://www.axios.com/2024/01/04/dea-weed-marijuana-legal-decriminalize-federal